Dive into December’s Topics
Translational Drug Development (TD2)
The Precision Oncology CRO
Welcome to the December Edition of TD2's Monthly Newsletter! As we wrap up the year 2023, our dedication to delivering the latest and most innovative content in cancer research continues to be our top priority. In this issue, you'll find a carefully curated collection of blogs, scientific posters, and videos, along with an opportunity to explore our featured services. Our goal is to propel forward in the field of oncology research and contribute to the development of revolutionary therapies. Stay connected and stay informed with us.
SCIENTIFIC POSTER
A Dual-specific Inhibitor of ROCK/AURK, RR-1752, for Primary Myelofibrosis
RR1752, a dual-specific inhibitor of ROCK and AURK, shows promise in treating myelofibrosis (MF) by effectively inhibiting colony formation in certain cell lines, decreasing specific phosphorylated proteins, inducing cell cycle arrest, and improving median survival in a mouse model without significant toxicity. The poster suggests that RR1752's on-target actions and favorable safety profile warrant further investigation for potential use in patients with myeloproliferative neoplasms.
FEATURED BLOG
The Critical Significance of DMPK Studies in Preclinical Research
Learn the strategic importance of initiating early DMPK analysis in preclinical studies to identify potential issues, the necessity of precise assay selection to evaluate various pharmacokinetic aspects, and the importance of adapting to technological advancements for comprehensive drug assessment.
SERVICE SPOTLIGHT
Next Generation Metabolomics and Proteomic Services
Metabolomics and proteomics analysis are crucial in preclinical cancer drug development as they provide comprehensive insights into the biochemical and protein changes induced by potential drugs, helping to understand their mechanisms of action and potential side effects. This detailed molecular-level information is essential for predicting drug efficacy and safety, thereby streamlining the development of more effective and targeted cancer therapies.
Translational Oncology Services
Learn more about TD2's Clinical Trial Management and Regulatory Support Services here.